Comparative Pharmacology
Head-to-head clinical analysis: AMANTADINE versus VITRASERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMANTADINE versus VITRASERT.
AMANTADINE vs VITRASERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
None Documented
None Documented
Clinical Note
moderateAmantadine + Haloperidol
"The therapeutic efficacy of Haloperidol can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Mifepristone
"Amantadine may increase the QTc-prolonging activities of Mifepristone."
Clinical Note
moderateAmantadine + Promazine
"The therapeutic efficacy of Promazine can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Chlorpromazine
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Category C
Category C
Antiviral / Antiparkinsonian
Antiviral
"The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Amantadine."